Jiangsu Hengrui Medicine Co. Ltd. to Put New Diabetes Drug in US ...
Aug 25, 2009 ... ChinaBio Today -- Jiangsu Hungrui Medicine (SHA: 600276) has been given ... Hengrui says that Retagliptin is an improved version of Merck's ...
www.biospace.com/news_story.aspx?NewsEntityId=1540...
• Found exclusively on: Google
FinancialContent.com - Stock Quotes and Business News
Jiangsu Hungrui Medicine received FDA approval to begin clinical trials of Retagliptin, a diabetes drug similar to Merck's Januvia; Wicon International ...
markets.hpcwire.com/c?Page=CHANNELINFO&ChannelID=3...
• Found exclusively on: Google
The Week in Review: US Clinical Trial of China Diabetes Drug ...
Jiangsu Hungrui Medicine received FDA approval to begin clinical trials of Retagliptin, a diabetes drug similar to Merck’s Januvia; Wicon International ...
www.chinabiotoday.com/articles/20090829
• Found exclusively on: Yahoo! Search
Hengrui Medicine to Put New Diabetes Drug in US Trials - ChinaBio ...
Aug 25, 2009 ... Jiangsu Hungrui Medicine (SHA: 600276) has been given FDA approval to begin a Phase I test of its innovative diabetes drug, Retagliptin.
www.chinabiotoday.com/articles/20090825
• Found exclusively on: Google
SeekingAlpha ETFs - China Biotech Takes an Important Step ...
... biopharma and a university.Jiangsu Hungrui Medicine (SHA: 600276) ... The drug, Retagliptin, is an improved version of Merck s (NYSE: MRK) Januvia, a mem...
www.inveslogic.com/sectors/directory/etf-investor/...
• Found exclusively on: Yahoo! Search
China Biotech Takes an Important Step: FDA Approved Clinical ...
Aug 30, 2009 ... Jiangsu Hungrui Medicine (SHA: 600276) is the company behind the first the drug given ... No trials have begun with Retagliptin in China. ...
seekingalpha.com/article/159063-china-biotech-take...
• Found exclusively on: Google
Simcere Pharmaceutical Group - SCR | Stock Market News
The drug, Retagliptin, is an improved... Simcere Teams Up with Cancer Center ... Simcere Pharmaceutical to acquire additional stake in Jiangsu - Trading Markets ...
stock-market-news.net/content/view/5642/
• Found exclusively on: Yahoo! Search
Emerginvest Featured Analysis: The Week in Review: US Clinical ...
Aug 29, 2009 ... Jiangsu Hungrui Medicine (SHA: 600276) is the company behind the first ... The drug, Retagliptin, is an improved version of Merck's (NYSE: ...
www.emerginvest.com/ChinaBioToday/8/29/2009/The_We...
• Found exclusively on: Google